Per Fischer, MinervaX CEO
October 11, 2023 03:00 AM EDTUpdated 05:39 AM
Financing

Phar­ma-backed Min­er­vaX rais­es €54M as it aims to move its group B Strep­to­coc­cus vac­cine in­to PhI­II

Katherine Lewin

News Reporter

Near­ly a year af­ter rais­ing its largest fi­nanc­ing so far, the Dan­ish biotech Min­er­vaX is back with an up­sized fi­nanc­ing round of €54 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times